The price you pay for Zeposia (ozanimod) may depend on factors such as whether you have health insurance and the pharmacy you use. Financial assistance may be available to help with the cost. The ...

Zeposia (ozanimod) is not safe to take while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can take the drug during this time. If you may be ...

Zeposia (ozanimod) is a prescription drug used to treat certain forms of multiple sclerosis (MS) in adults. Zeposia is a brand-name drug and is not currently available in a generic version. Zeposia ...

The US Food and Drug Administration (FDA) has approved ozanimod (Zeposia) for adults with moderately to severely active ulcerative colitis (UC), the company has announced. Ozanimod (0.92 mg), an oral ...

Bristol-Myers Squibb Company BMY announced that the FDA has granted approval to its sphingosine-1-phosphate (S1P) receptor modulator Zeposia (ozanimod) for the treatment of adult patients with ...

Bristol Myers Squibb announced the commercial launch of Zeposia (ozanimod) for relapsing multiple sclerosis (RMS). The oral treatment is the first and only approved sphingosine-1-phosphate receptor ...

As one of the hottest markets in pharmaceuticals, immunology has become a murderers' row of blockbuster drugs in recent years. But Bristol Myers Squibb has big hopes for a next-gen entry in Zeposia, ...

Bristol Myers Squibb (BMS) has shared new long-term data from a study evaluating Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (RMS). Approximately 2.5 million people ...

Please provide your email address to receive an email when new articles are posted on . Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved ...

Bristol-Myers Squibb Company BMY announced positive topline data from the pivotal phase III True North study, which evaluated its newly-approved multiple sclerosis drug Zeposia (ozanimod) for a new ...

The U.S. inflammatory bowel disease (IBD) market is seeing a shift in what drugs patients are offered for their first prescriptions. Doctors appear to be favoring the most recently approved drugs from ...